Literature DB >> 6172381

Mouse protection assay for group B streptococcus type III.

D O Fleming.   

Abstract

The mucin model for group B Streptococcus (GBS) type III was used to assay the protective effect of sera against a type III challenge in mice. Hyperimmune rabbit sera, prepared by the Lancefield method against the laboratory reference strain (SS620) and a clinical isolate (M732), protected against a lethal challenge with either strain of GBS type III. Absorption of the sera with either of these type III strains removed the protective effect. Neither normal rabbit sera nor heterologous antisera (anti-Ia, SS615) provided protection; however, protection was obtained with pooled human gamma globulin. Sera from adult volunteers were tested to assay protective levels in the mouse model. Human sera enhanced the mouse lethality of the clinical isolate, M732, but not the laboratory reference strain, SS620. Sera from adults vaccinated with type III polysaccharide of GBS were also tested. The murine-mucin-GBS model may be developed as a screening test to measure protective antibody levels in the pre- and postvaccine treatment period. The model may also be used to measure protective antibody in pooled human gamma globulin for use in the passive immunization of high-risk individuals.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6172381      PMCID: PMC351021          DOI: 10.1128/iai.35.1.240-247.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Microcapsule of type III strains of group B Streptococcus: production and morphology.

Authors:  C J Baker; D L Kasper
Journal:  Infect Immun       Date:  1976-01       Impact factor: 3.441

Review 2.  Group B streptococcus (S. agalactiae) bacteremia in adults: analysis of 32 cases and review of the literature.

Authors:  P I Lerner; K V Gopalakrishna; E Wolinsky; M C McHenry; J S Tan; M Rosenthal
Journal:  Medicine (Baltimore)       Date:  1977-11       Impact factor: 1.889

Review 3.  Group B streptococcal infections.

Authors:  C J Baker
Journal:  Adv Intern Med       Date:  1980

4.  Serious infections in adults due to group B streptococci. Clinical and serotypic characterization.

Authors:  A S Bayer; A W Chow; B F Anthony; L B Guze
Journal:  Am J Med       Date:  1976-10       Impact factor: 4.965

5.  Adult mice as a model for early onset group B streptococcal disease.

Authors:  D E Wennerstrom; R W Schutt
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

6.  Serious group B beta-hemolytic streptococcal infections in adults: report of two cases and review of the literature.

Authors:  J M Nicklas
Journal:  Johns Hopkins Med J       Date:  1978-02

7.  Detection of group B streptococcal antibodies in human sera by radioimmunoassay: concentrations of type-specific antibodies in sera of adults and infants infected with group B streptococci.

Authors:  H W Wilkinson
Journal:  J Clin Microbiol       Date:  1978-02       Impact factor: 5.948

8.  The natural history of group B streptococcal colonization in the pregnant woman and her offspring. II. Determination of serum antibody to capsular polysaccharide from type III, group B Streptococcus.

Authors:  C J Baker; B J Webb; D L Kasper; M D Yow; C W Beachler
Journal:  Am J Obstet Gynecol       Date:  1980-05-01       Impact factor: 8.661

9.  Mouse protection test for group B Streptococcus type III.

Authors:  R S Baltimore; D L Kasper; J Vecchitto
Journal:  J Infect Dis       Date:  1979-07       Impact factor: 5.226

10.  Group B streptococci in venereal disease clinic patients.

Authors:  J Wallin; A Forsgren
Journal:  Br J Vener Dis       Date:  1975-12
View more
  6 in total

1.  Deposition and degradation of C3 on type III group B streptococci.

Authors:  J R Campbell; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

2.  Capsular polysaccharide regulates neutrophil complement receptor interactions with type III group B streptococci.

Authors:  M S Edwards; M R Wessels; C J Baker
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

3.  Seroprevalence of antibodies to group B streptococcal polysaccharides in Gambian mothers and their newborns.

Authors:  R O Suara; R A Adegbola; E K Mulholland; B M Greenwood; C J Baker
Journal:  J Natl Med Assoc       Date:  1998-02       Impact factor: 1.798

4.  Type-specific protection of neonatal rats from lethal group B streptococcal infection by immune sera obtained from human volunteers vaccinated with type III-specific polysaccharide.

Authors:  B J De Cueninck; T K Eisenstein; T S McIntosh; G D Shockman; R M Swenson
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

5.  Human monoclonal antibodies to group B streptococcus. Reactivity and in vivo protection against multiple serotypes.

Authors:  H V Raff; P J Siscoe; E A Wolff; G Maloney; W Shuford
Journal:  J Exp Med       Date:  1988-09-01       Impact factor: 14.307

6.  Protection of mice from experimental infection with type III group B Streptococcus using monoclonal antibodies.

Authors:  M L Egan; D G Pritchard; H C Dillon; B M Gray
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.